Hospital
ST Lukes Quakertown Hospital
ST Lukes Quakertown Hospital was paid $3.56M by Medicaid between Jan 2020 and Dec 2024, across 75 billing codes. Its largest line is 99283, emergency room visit (moderate) — 59% of everything it billed.
33Billing provider infoST LUKES QUAKERTOWN HOSPITAL
QUAKERTOWN, PA 18951
QUAKERTOWN, PA 18951
33aNPI1669405072assigned 07/09/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$3.56M
24GClaims49,088
24DCodes billed75
24AFirst – last monthJan 2020 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in Pennsylvania
Rank by total paid#5 of 15
Median peer was paid$165K
This provider vs. median22×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WOLFE, SCOTT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 4,656 | $223K | |
| 2021 | 17,102 | $1.01M | |
| 2022 | 6,962 | $716K | |
| 2023 | 10,325 | $906K | |
| 2024incomplete | 10,043 | $703K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 59% | 14,939 | 14,243 | $2.11M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 5,548 | 5,356 | $679K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.4% | 1,892 | 1,812 | $228K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 5.9% | 6,370 | 1,830 | $211K |
| G0378 | Hospital observation service, per hour | 2.6% | 119 | 106 | $94K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | <1% | 717 | 677 | $31K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 293 | 283 | $30K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 213 | 200 | $24K |
| X0620 | <1% | 83 | 66 | $24K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 177 | 173 | $14K |
| 80053 | Comprehensive metabolic panel | <1% | 2,462 | 2,324 | $13K |
| 97162 | <1% | 195 | 175 | $13K |
63 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 256 | $11K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 3,204 | $9K |
| S9083 | Global fee urgent care centers | <1% | 73 | $9K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 98 | $6K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 167 | $6K |
| 97161 | <1% | 84 | $6K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 197 | $6K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 899 | $4K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 176 | $4K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 121 | $4K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 109 | $3K |
| 73564 | <1% | 149 | $2K | |
| 73630 | <1% | 259 | $2K | |
| 73610 | <1% | 167 | $2K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 232 | $2K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 30 | $2K |
| 73030 | <1% | 131 | $1K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 277 | $1K |
| 84484 | <1% | 358 | $1K | |
| 71045 | Radiologic examination, chest; single view | <1% | 357 | $1K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 242 | $908.85 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 98 | $848.50 |
| 36415 | Collection of venous blood by venipuncture | <1% | 858 | $788.70 |
| 85610 | <1% | 310 | $719.28 | |
| 83690 | <1% | 267 | $691.60 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 12 | $572.35 |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 78 | $536.99 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 57 | $520.59 |
| 71250 | <1% | 12 | $477.73 | |
| 73130 | <1% | 49 | $455.61 | |
| 81001 | <1% | 304 | $440.69 | |
| 85730 | <1% | 157 | $414.40 | |
| 73502 | <1% | 25 | $377.99 | |
| 72050 | <1% | 12 | $309.11 | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 12 | $216.30 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 18 | $210.40 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,226 | $187.62 |
| 85027 | <1% | 29 | $133.47 | |
| 80061 | Lipid panel | <1% | 15 | $123.51 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 37 | $123.28 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 101 | $100.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 98 | $89.81 |
| 83735 | <1% | 41 | $83.71 | |
| 81003 | <1% | 70 | $81.80 | |
| 82948 | <1% | 93 | $81.04 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,636 | $54.28 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,088 | $15.12 |
| 82077 | <1% | 15 | $10.53 | |
| 81025 | <1% | 39 | $2.77 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 237 | $2.01 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 48 | $0.02 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 399 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 38 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 125 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 260 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 32 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 72 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 20 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 131 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 194 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 156 | $0.00 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 0% | 12 | $0.00 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWOLFE, SCOTT (SENIOR VP FINANCE)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.